Navigation Links
Medivation Announces Pricing of Public Offering
Date:5/27/2009

SAN FRANCISCO, May 27 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the pricing of its public offering of 2,750,000 shares of its common stock at a public offering price of $21.00 per share. The company expects to complete the sale of these shares on or about June 2, 2009. The company has granted the underwriters a 30-day option to purchase 412,500 additional shares of common stock to cover over-allotments, if any.

J.P. Morgan Securities Inc. is acting as sole book-running manager of the offering.

The company currently expects to use the net proceeds of this offering for general corporate purposes, including to support further research, development and commercialization of its product candidates, including its lead product candidate, Dimebon, and its product candidate MDV3100.

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on August 3, 2007, that has been declared effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the prospectus supplement and related prospectus relating to the offering may be obtained from J.P. Morgan's prospectus department at 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, Attention Prospectus Department (telephone number 718-242-8002).

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there ar
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
2. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
3. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
4. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. Medivation Presents New Data on Dimebons Novel Mechanism of Action
6. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
7. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
8. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
9. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
10. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
11. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Global biostimulants market is expected ... an estimated CAGR of 12.5%. In order to ... with least ecological impacts, farmers are looking to ... crop yield more effectively & efficiently. Biostimulants are ... the return on investments. , Leading companies in ...
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... November 26, 2014 2014 Deep ... an in-depth research report on the Global Palmitic ... introduces Palmitic Acid, basic information, including definition, classification, ... and news analysis, etc. , For international ... Palmitic Acid market in China and other ...
(Date:11/26/2014)... , Nov. 25, 2014 Bio-Techne Corporation (NASDAQ: ... appointed Robert Gavin to serve in a ... Protein Platforms Division.  Mr. Gavin will be responsible for ... which includes the ProteinSimple business acquired in July 2014 ... San Jose, California -based ProteinSimple develops and ...
Breaking Biology Technology:2019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4SoundConnect Appoints Director of Channel Development & Sales 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... Victhom Human Bionics Inc., "Victhom" (TSX: VHB), today ... at www.victhom.com . The Website features a ... two operating divisions; Neurobionix, which is developing an ... which is developing and manufacturing computerized prostheses for ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that ... present a corporate update at the J.P. Morgan 27th Annual ... Pacific Time. The conference will be held January 12-15, ... Webcast of the presentation may be accessed on the Endo ...
... Inc. (OTC Bulletin Board: NWBO; AIM: NWBS and NWBT) (the ... class action lawsuit, In re Northwest Biotherapeutics, ... agreed to pay in settlement US$1 million, which is to ... be approved by the Court. Additional details about the ...
Cached Biology Technology:Victhom Announces Launch of Enhanced Company Website 2Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action 2Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action 3
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
(Date:11/2/2014)... , James Dacey explores the ways in which physicists ... innovations from the lab into the commercial market. , ... companies as they move from prototype to product is ... physics-based inventions are usually far from market-ready when initially ... lot more complicated than had been originally thought. , ...
(Date:11/2/2014)... put a flashlight up to our palms to see ... St. Louis engineers are using a similar idea to ... of cancerous tissues and to develop potential treatments. ... Professor of Biomedical Engineering at the School of Engineering ... that allows researchers to better focus light in tissue, ...
Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
... Children,s Research Institute and their collaborators have discovered a ... malformation syndrome that can make it impossible for the ... In a study led by Michael L. Cunningham, MD, ... Center, a research team pinpointed two genes known as ...
... the conditions that zebrafish are kept in could have ... the reliability of results, according to scientists from Queen ... mice, are often used by neuroscientists to explore mechanisms ... to treat behavioural disease such as addiction, attention deficit ...
... Health is seeking to refine and improve lung-cancer screening by ... earlier and more effectively. The trial combines a CT chest ... and seeks to build on recent research demonstrating that CT ... learned that CT screening of high-risk patients can reduce lung-cancer ...
Cached Biology News:Researchers pinpoint genetic pathway of rare facial malformation in children 2Better housing conditions for zebrafish could improve research results 2Better housing conditions for zebrafish could improve research results 3Trial seeks improved lung-cancer screening by combining imaging and biomarkers 2
... powerful solution for all plate washing needs in ... ,The PW 384 provides an excellent solution ... Drug Discovery (Assay development, Screening or Lead Optimization) ... ,The PW 384 has set a standard ...
... Model 1575 immunowash microplate washer, 100-240 V, ... have flat-, U-, or V-bottom wells. This ... needle positions to an accuracy of 0.1 ... overflow washing. It can store up to ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... MULTI-FUN Incubator is a compact ... uses a microprocessor controller with a ... temperature and agitation speed. Air circulation ... the incubator. Temperature can be easily ...
Biology Products: